Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis
- 30 September 1993
- journal article
- case report
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 29 (3), 477-480
- https://doi.org/10.1016/0190-9622(93)70215-f
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapyArthritis & Rheumatism, 1989
- Methotrexate Therapy for PsoriasisJAMA, 1988
- Methotrexate Therapy for PsoriasisJAMA, 1988
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988
- Folate status of rheumatoid arthritis patients receiving long‐term, low‐dose methotrexate therapyArthritis & Rheumatism, 1987
- Megaloblastic anaemia and methotrexate treatmentBritish Journal of Dermatology, 1986
- Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1985
- Commentary: Three Decades of Folic Acid Antagonists in DermatologyArchives of Dermatology, 1983
- Megaloblastic anaemia during methotrexate treatment of psoriasis.BMJ, 1966
- THE TREATMENT OF PSORIASIS WITH FOLIC ACID ANTAGONISTS.*British Journal of Dermatology, 1964